Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma

Combe, Pierre; Guillebon, Éléonore De; Thibault, Constance; Granier, Clémence; Tartour, Éric; Oudard, Stéphane

doi:10.1080/2162402x.2014.1001236

Cited by 21 publications

(19 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These include unspecific interleukin-2 (IL-2) therapy and specific strategies such as autologous vaccines and dendritic cell-based as well as RNA-or peptide-based approaches. [4][5][6][7][8] Recently, in a multipeptide vaccination phase II trial, overall patient survival was prolonged by the induction of specific T cell response. 9 Although a corresponding phase III trial did not confirm these results (data not published) other vaccination trials, e.g., in head and neck squamous cancer, showed induction of T cell response and prolonged overall survival.…”

Section: Introductionmentioning

confidence: 99%

Carcinogenesis of renal cell carcinoma reflected in HLA ligands: A novel approach for synergistic peptide vaccination design

et al. 2016

View full text Add to dashboard Cite

Despite recent advances in immunotherapy of renal cell carcinoma (RCC), peptide vaccination strategies still lack an approach for personalized peptide vaccination that takes intra-and inter-tumoral heterogeneity and biological characteristics into account. In this study, we use an immunoprecipitation and mass spectrometry-based approach supplemented by network analysis of HLA ligands to target this goal. By analyzing HLA-presented peptides for HLA class I and II of 11 malignant and 6 non-malignant kidney tissue samples, more than 2,700 peptides and 1,600 corresponding source proteins were identified.

show abstract

Section: Introductionmentioning

confidence: 99%

Carcinogenesis of renal cell carcinoma reflected in HLA ligands: A novel approach for synergistic peptide vaccination design

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Metastatic ccRCC is difficult to treat because it is highly resistant to systemic chemotherapy. No significant progress in overall patient survival has been achieved in the treatment of advanced or metastatic renal cell carcinoma . Understanding the genetic basis of ccRCC has significant implications for the diagnosis and treatment of this disease.…”

Section: Discussionmentioning

confidence: 99%

“…No significant progress in overall patient survival has been achieved in the treatment of advanced or metastatic renal cell carcinoma. 18 Understanding the genetic basis of ccRCC has significant implications for the diagnosis and treatment of this disease. The mutation rate of VHL is quite high in ccRCC, and the VHLhypoxia-inducible factor (HIF) pathway is the main mechanism in ccRCC carcinogenesis and target therapy.…”

Section: Discussionmentioning

confidence: 99%

Intrinsic gene changes determine the successful establishment of stable renal cancer cell lines from tumor tissue

et al. 2017

View full text Add to dashboard Cite

Human tumor cell lines, especially those with complete data and follow-up, are important tools in tumor biological studies. Clear cell renal cell cancer (ccRCC) is not sensitive to radiotherapy or chemotherapy, and treatment of patients with distant metastasis relies on targeted therapy. Here, we report the establishment of seven new ccRCC stable cell lines that were continuously cultured for more than 20 generations among 81 cases of renal cell cancer. Moreover, gene expression and methylation in the established cell lines, in those that had a finite in vitro life span of less than 10 generations, and in cells that originated from the same culture at different generations were profiled using microarrays. Genes including SLC34A2, SEPP1, SULT1C4 and others were differentially expressed in established cell lines and finite cell lines, and changes in their expression might be caused by methylation or demethylation. The expression level of SLC34A2 was related not only to the life span in vitro culture but also to tumor size. Additionally, six of the seven new ccRCC cell lines had VHL deletions or termination mutations. So in addition to the establishment of seven new ccRCC cell lines with complete clinical data, we conclude that genes such as SLC34A2 and VHL play key roles in the continuous in vitro growth and development of ccRCC.

show abstract

“…AGS-003 is a dendritic cell immunotherapeutic vaccine constructed from autologous blood dendritic cells and generated through the electroporation of tumor-derived RNA and CD40 ligands (CD40L) RNA into host immune cells [17][18][19]. The tumor RNA-loaded mature dendritic cells present patient tumor-specific antigens in T-cells via MHC I.…”

Section: Ags-003mentioning

confidence: 99%

Immunotherapy for Renal Cell Carcinoma

Qu¹,

Wu²,

He³

et al. 2020

Evolving Trends in Kidney Cancer

View full text Add to dashboard Cite

Despite the rapid development of therapeutic modalities for advanced or metastatic renal cell carcinoma (mRCC) over the past decade to include traditional immunotherapy, such as high-dose interleukin-2 and interferon-α, as well as a number of targeted antiangiogenic therapies, mRCC continues to be associated with poor prognosis. Currently, immunotherapy has seen tremendous development in the form of immune checkpoint inhibition and vaccines at a dizzying pace, which are being studied in mRCC and are showing promise as important steps in the management of this disease. With so many drugs available to clinicians and patients, properly integrating immunotherapy especially immune checkpoint blockade (ICB) into the treatment paradigm is challenging. Emerging research with additional ICB agents and novel combination strategies is likely to further impact clinical decision-making. The further development of biomarkers for predicting a response is required to achieve optimal efficacy with these therapeutic interventions. This chapter summarizes the current landscape of standard and emerging immune therapeutics and other modalities for mRCC.

show abstract

Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma

Cited by 21 publications

References 98 publications

Carcinogenesis of renal cell carcinoma reflected in HLA ligands: A novel approach for synergistic peptide vaccination design

Carcinogenesis of renal cell carcinoma reflected in HLA ligands: A novel approach for synergistic peptide vaccination design

Intrinsic gene changes determine the successful establishment of stable renal cancer cell lines from tumor tissue

Immunotherapy for Renal Cell Carcinoma

Contact Info

Product

Resources

About